$8.05
0.04[0.50%]
Last update: 11:23AM Get Real Time Here
Altimmune
(NASDAQ:ALT)Altimmune Stock (NASDAQ:ALT), Analyst Ratings, Price Targets, Predictions
Altimmune Inc has a consensus price target of $19.25, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., JMP Securities, and Guggenheim on May 14, 2024, May 10, 2024, and April 29, 2024. With an average price target of $12 between HC Wainwright & Co., JMP Securities, and Guggenheim, there's an implied 49.07% upside for Altimmune Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
Guggenheim
B. Riley Securities
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Altimmune
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | 49.07% | HC Wainwright & Co. | Patrick Trucchio | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 198.14% | JMP Securities | Jonathan Wolleben | $25 → $24 | Maintains | Market Outperform | Get Alert |
| 04/29/2024 | Buy Now | — | Guggenheim | Seamus Fernandez | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2024 | Buy Now | 49.07% | HC Wainwright & Co. | Patrick Trucchio | $15 → $12 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | 148.45% | B. Riley Securities | Mayank Mamtani | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2024 | Buy Now | 148.45% | B. Riley Securities | Mayank Mamtani | → $20 | Maintains | Buy | Get Alert |
| 01/24/2024 | Buy Now | 61.49% | Goldman Sachs | Corinne Jenkins | → $13 | Reinstates | → Neutral | Get Alert |
| 12/01/2023 | Buy Now | 86.34% | HC Wainwright & Co. | Patrick Trucchio | → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | -0.62% | B. Riley Securities | Mayank Mamtani | $15 → $8 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 86.34% | HC Wainwright & Co. | Patrick Trucchio | $50 → $15 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 86.34% | B. Riley Securities | Mayank Mamtani | $20 → $15 | Maintains | Buy | Get Alert |
| 07/12/2023 | Buy Now | 86.34% | JMP Securities | Jonathan Wolleben | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/15/2023 | Buy Now | 521.12% | HC Wainwright & Co. | Patrick Trucchio | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 86.34% | JMP Securities | Jonathan Wolleben | $15 → $15 | Reinstates | Market Outperform → Market Outperform | Get Alert |
| 03/31/2023 | Buy Now | 86.34% | JMP Securities | Jonathan Wolleben | → $15 | Reiterates | → Market Outperform | Get Alert |
| 03/22/2023 | Buy Now | 222.98% | JMP Securities | Jonathan Wolleben | → $26 | Reiterates | → Market Outperform | Get Alert |
| 03/22/2023 | Buy Now | -25.47% | Goldman Sachs | Corinne Jenkins | $20 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/09/2023 | Buy Now | 521.12% | HC Wainwright & Co. | Patrick Trucchio | → $50 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 222.98% | JMP Securities | Jonathan Wolleben | → $26 | Reiterates | → Market Outperform | Get Alert |
| 01/20/2023 | Buy Now | 521.12% | HC Wainwright & Co. | Patrick Trucchio | → $50 | Reiterates | → Buy | Get Alert |
| 01/18/2023 | Buy Now | 210.56% | Evercore ISI Group | Liisa Bayko | $14 → $25 | Maintains | Outperform | Get Alert |
| 12/01/2022 | Buy Now | 148.45% | Goldman Sachs | Corinne Jenkins | → $20 | Initiates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 222.98% | JMP Securities | Jonathan Wolleben | $28 → $26 | Maintains | Market Outperform | Get Alert |
| 09/16/2022 | Buy Now | 222.98% | Guggenheim | Seamus Fernandez | $31 → $26 | Maintains | Buy | Get Alert |
| 08/31/2022 | Buy Now | 334.78% | Jefferies | Roger Song | $30 → $35 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | 521.12% | HC Wainwright & Co. | Patrick Trucchio | $25 → $50 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | 222.98% | B. Riley Securities | Mayank Mamtani | $21 → $26 | Maintains | Buy | Get Alert |
| 05/18/2022 | Buy Now | 210.56% | Piper Sandler | Yasmeen Rahimi | $34 → $25 | Maintains | Overweight | Get Alert |
| 06/30/2021 | Buy Now | 160.87% | B. Riley Securities | Mayank Mamtani | — | Maintains | Buy | Get Alert |
| 06/30/2021 | Buy Now | 285.09% | JMP Securities | Jonathan Wolleben | — | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Altimmune (ALT)?
The latest price target for Altimmune (NASDAQ: ALT) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $12.00 expecting ALT to rise to within 12 months (a possible 49.07% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Altimmune (ALT)?
The latest analyst rating for Altimmune (NASDAQ: ALT) was provided by HC Wainwright & Co., and Altimmune reiterated their buy rating.
When was the last upgrade for Altimmune (ALT)?
There is no last upgrade for Altimmune.
When was the last downgrade for Altimmune (ALT)?
The last downgrade for Altimmune Inc happened on April 29, 2024 when Guggenheim changed their price target from N/A to N/A for Altimmune Inc.
When is the next analyst rating going to be posted or updated for Altimmune (ALT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Altimmune (ALT) correct?
While ratings are subjective and will change, the latest Altimmune (ALT) rating was a reiterated with a price target of $0.00 to $12.00. The current price Altimmune (ALT) is trading at is $8.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.